Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma)

Rheumatoid Arthritis (and broader TNF-driven autoimmune disease)

$20.4B Humira global net sales 2020 (post-acquisition asset peak; $20.4B)

Disease Overview

Rheumatoid arthritis is a chronic autoimmune disease in which the immune system attacks synovial joint linings, driving inflammation, pain, joint destruction, and disability. It affects roughly 1.3 million US adults, disproportionately women. TNF-alpha is a master inflammatory cytokine in RA pathology, making TNF inhibition the foundational biologic mechanism. The Knoll/BASF-discovered D2E7 (later adalimumab/Humira) was the first fully human anti-TNF monoclonal antibody.

Competitive Landscape

At the time of Abbott's March 2001 close of Knoll, the TNF-inhibitor RA market was emerging. Johnson & Johnson/Centocor's Remicade (infliximab, chimeric mAb) had launched in 1998, and Immunex/Wyeth's Enbrel (etanercept, soluble TNF receptor fusion) launched in 1999. Knoll's pipeline asset D2E7 — co-developed with Cambridge Antibody Technology — was Phase III, distinguished by being the first fully human anti-TNF monoclonal, dosed subcutaneously every other week. Wall Street initially derided the deal: Abbott shares fell 7.1% on announcement and Salomon Smith Barney analysts publicly questioned dilution and execution, with consensus pegging eventual D2E7 peak sales at just ~$1B. The deal also added Synthroid (levothyroxine) for hypothyroidism, Mavik/Tarka for hypertension, and Meridia for obesity. FDA approved adalimumab as Humira in December 2002 for RA and it later expanded across psoriasis, Crohn's, ulcerative colitis, ankylosing spondylitis, JIA, hidradenitis suppurativa, and uveitis. Humira became the world's top-selling drug 2012-2020, generating ~$231B in cumulative net sales — repositioning Abbott (and later spinoff AbbVie) as a top-tier biologics franchise versus competitors J&J, Amgen, and emerging biosimilar entrants.